Most Read Articles
Natalia Reoutova, 21 Nov 2019

Final analysis of the POEMS (Prevention of Early Menopause) study finds that breast cancer (BC) patients treated with the gonadotrophin-releasing hormone agonist (GnRHa) goserelin, in addition to chemotherapy, are more likely to avoid premature menopause and to become pregnant without negatively impacting disease-related outcomes.

Jairia Dela Cruz, 4 days ago
In breast cancer, especially hormone-negative tumours, an ultrasound-guided core biopsy (CNB) is useful for predicting pathologic complete response (pCR) to chemotherapy and may thus help to avoid surgery for some patients, a study has found.
Christina Lau, 08 Dec 2016

Icotinib improves progression-free survival (PFS) and objective response rate (ORR) vs whole-brain irradiation (WBI) plus chemotherapy in Chinese patients with non-small-cell lung cancer (NSCLC) and brain metastases, according to a phase III study presented recently at the 17th World Conference on Lung Cancer (WCLC).

Christina Lau, 14 Feb 2019
Progress in the treatment of rare cancers has been named Advance of the Year by the American Society of Clinical Oncology (ASCO).

Stigma strong against lung cancer patients

06 Nov 2019
Lung cancer patients suffer from stigma, which compromises their self-esteem and self-efficacy, according to a recent China study.

Researchers enrolled 283 lung cancer patients (mean age, 52.98±11.08 years; 61.5 percent male) who were asked to complete questionnaires that collected, among other things, demographic variables, disease disclosure, negative changes in body image or family relationships, and perceived blame. The social impact scale (SIS) was used to measure lung cancer stigma.

More than a third (39.6 percent) of the participants hid their diagnosis from others, while almost all reported negative changes in economic burden (91.5 percent) and body image (90.8 percent). Almost a quarter (23.7 percent) reported perceived blame. The mean SIS score was 2.38±0.45, indicating moderate stigma.

Stigma was significantly and negatively correlated with patient self-esteem (r, –0.607; p<0.001) and coping self-efficacy (r, –0.424; p<0.001).

Multiple linear regression analysis confirmed that elevated levels of stigma were significantly associated with poor self-esteem (adjusted r2, 0.367; p<0.001) and coping self-efficacy (adjusted r2, 0.470; p=0.028).

Other significant correlates of stigma included younger age (adjusted r2, 0.476; p=0.037), higher cancer stage (adjusted r2, 0.463; p=0.019), perceived blame (adjusted r2, 0.436; p=0.002), concealment of diagnosis (adjusted r2, 0.455; p=0.01), and greater negative impacts on financial burden (adjusted r2, 0.420; p=0.001), body image (adjusted r2, 0.446; p=0.051) and family relationship (adjusted r2, 0.482; p=0.049).

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Natalia Reoutova, 21 Nov 2019

Final analysis of the POEMS (Prevention of Early Menopause) study finds that breast cancer (BC) patients treated with the gonadotrophin-releasing hormone agonist (GnRHa) goserelin, in addition to chemotherapy, are more likely to avoid premature menopause and to become pregnant without negatively impacting disease-related outcomes.

Jairia Dela Cruz, 4 days ago
In breast cancer, especially hormone-negative tumours, an ultrasound-guided core biopsy (CNB) is useful for predicting pathologic complete response (pCR) to chemotherapy and may thus help to avoid surgery for some patients, a study has found.
Christina Lau, 08 Dec 2016

Icotinib improves progression-free survival (PFS) and objective response rate (ORR) vs whole-brain irradiation (WBI) plus chemotherapy in Chinese patients with non-small-cell lung cancer (NSCLC) and brain metastases, according to a phase III study presented recently at the 17th World Conference on Lung Cancer (WCLC).

Christina Lau, 14 Feb 2019
Progress in the treatment of rare cancers has been named Advance of the Year by the American Society of Clinical Oncology (ASCO).